We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.75%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.44B
AUM Growth
-$102M
Cap. Flow
-$54M
Cap. Flow %
-2.21%
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$45.2M
2
HUM icon
Humana
HUM
+$23.9M
3
LLY icon
Eli Lilly
LLY
+$20.3M
4
ILMN icon
Illumina
ILMN
+$20.1M
5
ABT icon
Abbott
ABT
+$17.5M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$44.1M
2
UNH icon
UnitedHealth
UNH
+$23.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$23.1M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$21.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$21.3M

Sector Composition

Rank Sector Weight
1 Healthcare 96.9%
2 Real Estate 1.86%
3 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UNH icon
1
UnitedHealth
UNH
$383B
$138M 5.67%
274,046
-45,464
-14% -$23.9M
JNJ icon
2
Johnson & Johnson
JNJ
$617B
$128M 5.24%
783,779
+267,127
+52% +$45.2M
AMGN icon
3
Amgen
AMGN
$209B
$117M 4.79%
518,869
-29,549
-5% -$7.16M
GILD icon
4
Gilead Sciences
GILD
$163B
$100M 4.1%
1,622,165
-28,600
-2% -$1.8M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$122B
$90.7M 3.71%
313,403
-47,828
-13% -$13.8M
LLY icon
6
Eli Lilly
LLY
$1.03T
$77.8M 3.18%
240,578
+64,146
+36% +$20.3M
ABT icon
7
Abbott
ABT
$183B
$76.5M 3.13%
791,051
+163,759
+26% +$17.5M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$77.4B
$75.1M 3.08%
109,062
-33,802
-24% -$21.3M
ABBV icon
9
AbbVie
ABBV
$455B
$70.7M 2.89%
526,842
-40,000
-7% -$5.74M
AZN icon
10
AstraZeneca
AZN
$266B
$69.8M 2.86%
636,597
+74,226
+13% +$9.42M
BMY icon
11
Bristol-Myers Squibb
BMY
$132B
$62.5M 2.56%
879,476
+96,741
+12% +$7.02M
CI icon
12
Cigna
CI
$76.1B
$58.5M 2.39%
210,731
+37,625
+22% +$10.6M
ILMN icon
13
Illumina
ILMN
$31B
$56.3M 2.3%
303,201
+101,665
+50% +$20.1M
HUM icon
14
Humana
HUM
$44B
$54.8M 2.24%
113,004
+49,210
+77% +$23.9M
PFE icon
15
Pfizer
PFE
$142B
$49.5M 2.03%
1,132,103
– –
MRK icon
16
Merck
MRK
$321B
$47.5M 1.95%
552,122
– –
TMO icon
17
Thermo Fisher Scientific
TMO
$214B
$47.5M 1.95%
93,705
-3,900
-4% -$2.18M
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$45.4M 1.86%
734,353
-141,736
-16% -$9.9M
MOH icon
19
Molina Healthcare
MOH
$10.2B
$39.4M 1.61%
119,535
+14,450
+14% +$4.65M
SYK icon
20
Stryker
SYK
$133B
$39.2M 1.6%
193,528
-32,150
-14% -$6.76M
BIIB icon
21
Biogen
BIIB
$30.7B
$38.8M 1.59%
145,439
+9,800
+7% +$2.08M
MRNA icon
22
Moderna
MRNA
$23B
$37.2M 1.52%
314,924
-13,600
-4% -$2.06M
DHR icon
23
Danaher
DHR
$138B
$32.2M 1.32%
140,499
– –
BSX icon
24
Boston Scientific
BSX
$68.4B
$30.8M 1.26%
795,215
– –
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$27.4B
$28.7M 1.17%
143,214
+14,800
+12% +$2.82M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Tekla Capital Management held 187 positions worth $2.44B, down 4% from $2.54B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q3 2022 filing shows 10 new, 35 increased, 38 reduced and 19 closed positions. Its largest new stake was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M. The largest sale was McKesson, an estimated $44.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q3 2022 buy was Veradigm Inc. Common Stock: 428,580 shares worth $6.53M.
  • Tekla Capital Management added most to Johnson & Johnson in Q3 2022, an estimated $45.2M increase.
  • Tekla Capital Management's biggest Q3 2022 reduction was McKesson, cutting an estimated $44.1M.
  • Tekla Capital Management fully exited Syneos Health, Inc. Class A Common Stock in Q3 2022, selling an estimated $21.7M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.44B portfolio in Q3 2022.
  • Tekla Capital Management opened 10 new positions and closed 19 in Q3 2022.
  • Tekla Capital Management's portfolio value fell 4% quarter-over-quarter to $2.44B.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.